Withdrawal symptoms of antidepressants;Onttrekkingsverschijnselen van antidepressiva

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 13, 2005, Pages 698-701

  Vlaminck, J J D ^a   Van Vliet I M ^b   Zitman, F G ^b  

^a GGZ Groep Europoort Ensis   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BALANCE DISORDER; DEPRESSION; EXTRAPYRAMIDAL SYNDROME; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; MENTAL DISEASE; PATIENT INFORMATION; PROPHYLAXIS; REVIEW; SLEEP DISORDER; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 16344396615     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Gebruik van antidepressiva 1996-2001. Genees- en hulpmiddelen Informatie Project (GIP). GIP-signaal nr 4. Diemen: College voor zorgverzekeringen; 2003.
2. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997;58 Suppl 7:17-21.
3. Dilsaver SC. Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatr Scand 1988;78:1-7.
4. Lejoyeux M, Adès J, Mourad L, Solomon I, Dilsaver S. Antidepressant withdrawal syndrome: recognition, prevention and management. Drug Ther 1997;5:278-91.
5. Curtin F, Berney P, Kaufmann C. Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms. J Psychopharmacol 2002;16:271-2.
6. Bialos D, Giller E, Jatlow P, Docherty J, Harkness L. Recurrence of depression after discontinuation of long-term amitriptyline treatment. Am J Psychiatry 1982;139:325-9.
7. Kramer JC, Klein DF, Fink M. Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961;118:549-50.
8. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-62.
9. Geller B, Cooper TB, Carr LG, Warham JE, Rodriguez A. Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. J Clin Psychopharmacol 1987;7:252-4.
10. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87.
11. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000;15:305-18.
12. Bogetto F, Bellino S, Revello RB, Patria L. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002;16:273-83.
13. Vergouwen AC, Bakker A. Selectieve serotonineheropnameremmers en onttrekkingsverschijnselen. Tijdschrift voor Psychiatrie 2000;42:845-9.
14. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-9.
15. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997;154:1760-2.
16. Dilsaver SC, Greden JF. Antidepressant withdrawal syndromes: evidence for supersensitivity of cholinergic system as an etiologic factor. J Clin Psychopharmacol 1983;3:330.
17. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry 1997;58:23-7.
18. Harvey BH, McEwen BS, Stein DJ. Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression. Biol Psychiatry 2003;54:1105-17.
19. Michelson D, Amsterdam J, Apter J, Fava M, Londborg P, Tamura R, et al. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology 2000;25:169-77.
20. Nordeng H, Lindemann R, Perminov KV, Reik A van. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Act Paediatr 2001;90:288-91.
21. Moor RA de, Mourad L, Haar J ter, Egberts ACG. Onthoudingsverschijnselen bij een neonatus na blootstelling aan venlafaxine tijdens de zwangerschap. Ned Tijdschr Geneeskd 2003;147:1370-2.
22. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry 1997;171:391-2.
23. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720-6.